scholarly journals New Approach to Drug Discovery of a Safe Mitochondrial Uncoupler: OPC-163493

ACS Omega ◽  
2021 ◽  
Author(s):  
Takashi Okamoto ◽  
Takahiro Shimada ◽  
Chiharu Matsumura ◽  
Hitomi Minoshima ◽  
Takashi Ban ◽  
...  
Keyword(s):  
Drug Discovery ◽  
New Approach ◽  
Mitochondrial Uncoupler

Drug Discovery

2018 ◽  
pp. 399-404
Author(s):  
S. Nassir Ghaemi
Keyword(s):  
Drug Discovery ◽  
Pharmaceutical Industry ◽  
Discovery Process ◽  
Drug Discovery Process ◽  
New Approach ◽  
The Past ◽  
Scientific Exploration ◽  
Clinical Indications ◽  
The Future ◽  
Clinical Diagnoses

Newer and better medications are obtained as part of the drug discovery process, which occurs mainly in the pharmaceutical industry. This process is hampered by excessive attention to marketing demands, as opposed to scientific exploration. It also is impaired by the psychiatric profession’s mistaken ideologies, whether psychoanalytic orthodoxy in the past or DSM beliefs of the present. Wrong clinical phenotypes impair finding new pharmacological mechanisms and targeting them well to the write clinical indications. Perhaps as a consequence, no treatments have been developed in the last few decades, since DSM-III, that are more effective than prior agents. Progress for the future in drug discovery will require not just better neurobiological work, but also a new approach to clinical diagnoses in psychiatry.

scholarly journals Drug Discovery Testing Compounds in Patient Samples by Automated Flow Cytometry

2017 ◽  
Vol 22 (3) ◽  
pp. 325-337 ◽  
Author(s):  
Pilar Hernández ◽  
Julián Gorrochategui ◽  
Daniel Primo ◽  
Alicia Robles ◽  
José Luis Rojas ◽  
...  
Keyword(s):  
Flow Cytometry ◽  
Drug Discovery ◽  
Hematological Malignancies ◽  
Ex Vivo ◽  
Multiple Endpoints ◽  
New Approach ◽  
Analysis System ◽  
Data Analysis System ◽  
Predictive Assay ◽  
Ex Vivo Testing

Functional ex vivo assays that predict a patient’s clinical response to anticancer drugs for guiding cancer treatment have long been a goal, but few have yet proved to be reliable. To address this, we have developed an automated flow cytometry platform for drug screening that evaluates multiple endpoints with a robust data analysis system that can capture the complex mechanisms of action across different compounds. This system, called PharmaFlow, is used to test peripheral blood or bone marrow samples from patients diagnosed with hematological malignancies. Functional assays that use the whole sample, retaining all the microenvironmental components contained in the sample, offer an approach to ex vivo testing that may give results that are clinically relevant. This new approach can help to predict the patients’ response to existing treatments or to drugs under development, for hematological malignancies or other tumors. In addition, relevant biomarkers can be identified that determine the patient’s sensitivity, resistance, or toxicity to a given treatment. We propose that this approach, which better recapitulates the human microenvironment, constitutes a more predictive assay for personalized medicine and preclinical drug discovery.

Metal-organic compounds: a new approach for drug discovery

2002 ◽  
Vol 63 (10) ◽  
pp. 1863-1873 ◽  
Author(s):  
Florence Lebon ◽  
Nicole Boggetto ◽  
Marie Ledecq ◽  
François Durant ◽  
Zohra Benatallah ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Organic Compounds ◽  
New Approach ◽  
Metal Organic

scholarly journals A new approach to the classification and management of airways diseases: identification of treatable traits

2017 ◽  
Vol 131 (10) ◽  
pp. 1027-1043 ◽  
Author(s):  
Rahul Shrimanker ◽  
Xue Ning Choo ◽  
Ian D. Pavord
Keyword(s):  
Drug Discovery ◽  
Current Approach ◽  
Targeted Intervention ◽  
New Approach ◽  
Healthcare Settings ◽  
Airway Diseases ◽  
Fit For Purpose ◽  
Diagnostic Label ◽  
Personalized Approach ◽  
Do So

This review outlines a new, personalized approach for the classification and management of airway diseases. The current approach to airways disease is, we believe, no longer fit for purpose. It is impractical, overgeneralizes complex and heterogeneous conditions and results in management that is imprecise and outcomes that are worse than they could be. Importantly, the assumptions we make when applying a diagnostic label have impeded new drug discovery and will continue to do so unless we change our approach. This review suggests a new mechanism-based approach where the emphasis is on identification of key causal mechanisms and targeted intervention with treatment based on possession of the relevant mechanism rather than an arbitrary label. We highlight several treatable traits and suggest how they can be identified and managed in different healthcare settings.

scholarly journals Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem

2017 ◽  
Vol 32 (5) ◽  
pp. 974-984 ◽  
Author(s):  
Sarah J. Martins da Silva ◽  
Sean G. Brown ◽  
Keith Sutton ◽  
Louise V. King ◽  
Halil Ruso ◽  
...  
Keyword(s):  
Drug Discovery ◽  
High Throughput ◽  
High Throughput Screening ◽  
Unsolved Problem ◽  
New Approach ◽  
Male Subfertility

scholarly journals Nano-sized Molecule: New Approach for Diagnosis and Drug Discovery

2013 ◽  
Vol 133 (3) ◽  
pp. 349-349 ◽  
Author(s):  
Hiroshi Abe ◽  
Shin Mizukami
Keyword(s):  
Drug Discovery ◽  
New Approach

A new approach for drug discovery from glycobiology and phage-displayed peptide library technology

2008 ◽  
Vol 1780 (3) ◽  
pp. 497-503 ◽  
Author(s):  
Takao Taki ◽  
Dai Ishikawa ◽  
Koichi Ogino ◽  
Michinori Tanaka ◽  
Naoto Oku ◽  
...  
Keyword(s):  
Drug Discovery ◽  
Peptide Library ◽  
New Approach ◽  
Phage Displayed Peptide Library ◽  
Library Technology
Sign in / Sign up

Export Citation Format

Share Document